432
Views
45
CrossRef citations to date
0
Altmetric
Perspective

Influenza viral neuraminidase: the forgotten antigen

&
Pages 1683-1695 | Published online: 09 Jan 2014

References

  • La Montagne JR, Noble GR, Quinnan GV et al. Summary of clinical trials of inactivated influenza vaccine – 1978. Rev. Infect. Dis.5(4), 723–736 (1983).
  • Quinnan GV, Schooley R, Dolin R, Ennis FA, Gross P, Gwaltney JM. Serologic responses and systemic reactions in adults after vaccination with monovalent A/USSR/77 and trivalent A/USSR/77, A/Texas/77, B/Hong Kong/72 influenza vaccines. Rev. Infect. Dis.5(4), 748–757 (1983).
  • Frank JW. Explaining vaccine failures – the use of a sports analogy. Can. J. Pub. Health76(2), 130–132 (1985).
  • Madjid M, Naghavi M, Litovsky S, Casscells SW. Influenza and cardiovascular disease: a new opportunity for prevention and the need for further studies. Circulation108(22), 2730–2736 (2003).
  • Naghavi M, Wyde P, Litovsky S et al. Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein E-deficient mice. Circulation107(5), 762–768 (2003).
  • Mostow SR. Influenza – a preventable disease not being prevented. Am. Rev. Respir. Dis.134(1), 1 (1986).
  • Fiore AE, Shay DK, Broder K et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm. Rep.57(RR-7), 1–60 (2008).
  • Gani R, Hughes H, Fleming D, Griffin T, Medlock J, Leach S. Potential impact of antiviral drug use during influenza pandemic. Emerg. Infect. Dis.11(9), 1355–1362 (2005).
  • Kiso M, Mitamura K, Sakai-Tagawa Y et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet364(9436), 759–765 (2004).
  • Besselaar TG, Naidoo D, Buys A et al. Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa. Emerg. Infect. Dis.14(11), 1809–1810 (2008).
  • Hurt AC, Ernest J, Deng YM et al. Emergence and spread of oseltamivir-resistant A (H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res.83(1), 90–93 (2009).
  • Choppin PW, Murphy JS, Tamm I. Studies of two kinds of virus particles which comprise influenza A2 virus strains. III. Morphological characteristics: independence to morphological and functional traits. J. Exp. Med.112, 945–952 (1960).
  • Choppin PW, Tamm I. Studies of two kinds of virus particles which comprise influenza A2 virus strains. II. Reactivity with virus inhibitors in normal sera. J. Exp. Med.112, 921–944 (1960).
  • Gottschalk A. Neuraminidase: the specific enzyme of influenza virus and Vibrio cholerae. Biochim. Biophys. Acta23(3), 645–646 (1957).
  • Kilbourne ED. Influenza pandemics of the 20th century. Emerg. Infect. Dis.12(1), 9–14 (2006).
  • Kilbourne ED. Influenza immunity: new insights from old studies. J. Infect. Dis.193(1), 7–8 (2006).
  • Baum LG, Paulson JC. The N2 neuraminidase of human influenza virus has acquired a substrate specificity complementary to the hemagglutinin receptor specificity. Virology180(1), 10–15 (1991).
  • Xu G, Suzuki T, Maejima Y et al. Sialidase of swine influenza A viruses: variation of the recognition specificities for sialyl linkages and for the molecular species of sialic acid with the year of isolation. Glycoconj. J.12(2), 156–161 (1995).
  • Gambaryan AS, Matrosovich MN, Bender CA, Kilbourne ED. Differences in the biological phenotype of low-yielding (L) and high-yielding (H) variants of swine influenza virus A/NJ/11/76 are associated with their different receptor-binding activity. Virology247(2), 223–231 (1998).
  • Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J. Virol.78(22), 12665–12667 (2004).
  • Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc. Natl Acad. Sci. USA101(13), 4620–4624 (2004).
  • Schulman JL, Khakpour M, Kilbourne ED. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J. Virol.2(8), 778–786 (1968).
  • Lamb RA, Choppin PW. The gene structure and replication of influenza virus. Ann. Rev. Biochem.52, 467–506 (1983).
  • Lamb RA, Zebedee SL, Richardson CD. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell40(3), 627–633 (1985).
  • Zebedee SL, Richardson CD, Lamb RA. Characterization of the influenza virus M2 integral membrane protein and expression at the infected-cell surface from cloned cDNA. J. Virol.56(2), 502–511 (1985).
  • Liu W, Li H, Chen YH. N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS Immunol. Med. Microbiol.35(2), 141–146 (2003).
  • Black RA, Rota PA, Gorodkova N, Cramer A, Klenk HD, Kendal AP. Production of the M2 protein of influenza A virus in insect cells is enhanced in the presence of amantadine. J. Gen. Virol.74(Pt 8), 1673–1677 (1993).
  • Black RA, Rota PA, Gorodkova N, Klenk HD, Kendal AP. Antibody response to the M2 protein of influenza A virus expressed in insect cells. J. Gen. Virol.74(Pt 1), 143–146 (1993).
  • Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med.5(10), 1157–1163 (1999).
  • Boulo S, Akarsu H, Ruigrok RW, Baudin F. Nuclear traffic of influenza virus proteins and ribonucleoprotein complexes. Virus Res.124(1–2), 12–21 (2007).
  • Chen W, Calvo PA, Malide D et al. A novel influenza A virus mitochondrial protein that induces cell death. Nat. Med.7(12), 1306–1312 (2001).
  • Wang X, Li M, Zheng H et al. Influenza A virus NS1 protein prevents activation of NF-κB and induction of α/β interferon. J. Virol.74(24), 11566–11573 (2000).
  • Hobson D, Baker FA, Chivers CP, Reed SE, Sharp D. A comparison of monovalent Hong Kong influenza virus vaccine with vaccines containing only pre-1968 Asian strains in adult volunteers. A report to the Medical research council committee on influenza and other respiratory virus vaccines. J. Hyg. (Lond.)68(3), 369–378 (1970).
  • Hobson D, Baker FA, Curry RL. Effect of influenza vaccines in stimulating antibody in volunteers with prior immunity. Lancet2(7821), 155–156 (1973).
  • Hobson D, Baker FA, Curry RL, Beare AS, Massey PM. The efficacy of live and inactivated vaccines of Hong Kong influenza virus in an industrial community. A report to the Medical research council committee on influenza and other respiratory virus vaccines. J. Hyg. (Lond.)71(4), 641–647 (1973).
  • Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. (Lond.)70(4), 767–777 (1972).
  • Eichelberger M, Golding H, Hess M et al. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development. Bethesda, Maryland, US, December 10–11, 2007. Vaccine26(34), 4299–4303 (2008).
  • Hassantoufighi A, Zhang H, Sandbulte M et al. A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses. Vaccine28(3), 790–797 (2010).
  • Gavrilov V, Orekov T, Alabanza C et al. Influenza virus-like particles as a new tool for vaccine immunogenicity testing: validation of a neuraminidase neutralizing antibody assay. J. Virol. Methods173(2), 364–373 (2011).
  • Mandler J, Scholtissek C. Localisation of the temperature-sensitive defect in the nucleoprotein of an influenza A/FPV/Rostock/34 virus. Virus Res.12(2), 113–121 (1989).
  • Johansson BE, Kilbourne ED. Immunization with dissociated neuraminidase, matrix, and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition. Virology225(1), 136–144 (1996).
  • Lawson CM, Bennink JR, Restifo NP, Yewdell JW, Murphy BR. Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge. J. Virol.68(6), 3505–3511 (1994).
  • Lin YL, Askonas BA. Biological properties of an influenza A virus-specific killer T cell clone. Inhibition of virus replication in vivo and induction of delayed-type hypersensitivity reactions. J. Exp. Med.154(2), 225–234 (1981).
  • Mcmichael AJ, Gotch F, Cullen P, Askonas B, Webster RG. The human cytotoxic T cell response to influenza A vaccination. Clin. Exp. Immunol.43(2), 276–284 (1981).
  • Mcmurry JA, Johansson BE, De Groot AS. A call to cellular & humoral arms: enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A. Hum. Vaccin.4(2), 148–157 (2008).
  • Johansson BE, Moran TM, Bona CA, Popple SW, Kilbourne ED. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience. J. Immunol.139(6), 2010–2014 (1987).
  • Johansson BE, Moran TM, Kilbourne ED. Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. Proc. Natl Acad. Sci. USA84(19), 6869–6873 (1987).
  • Russell SM, Liew FY. Cell cooperation in antibody responses to influenza virus. I. priming of helper T cells by internal components of virion. Eur. J. Immunol.10(10), 791–796 (1980).
  • Russell SM, Liew FY. T cells primed by influenza virion internal components can cooperate in the antibody response to haemagglutinin. Nature280(5718), 147–148 (1979).
  • Scherle PA, Gerhard W. Functional analysis of influenza-specific helper T cell clones in vivo. T cells specific for internal viral proteins provide cognate help for B cell responses to hemagglutinin. J. Exp. Med.164(4), 1114–1128 (1986).
  • Ross TM, Mahmood K, Crevar CJ, Schneider-Ohrum K, Heaton PM, Bright RA. A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS One4(6), e6032 (2009).
  • Bright RA, Carter DM, Daniluk S et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine25(19), 3871–3878 (2007).
  • Pushko P, Tumpey TM, Van Hoeven N et al. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine25(21), 4283–4290 (2007).
  • Ulmer JB, Fu TM, Deck RR et al. Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J. Virol.72(7), 5648–5653 (1998).
  • Montgomery DL, Shiver JW, Leander KR et al. Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol.12(9), 777–783 (1993).
  • Bender BS, Ulmer JB, Dewitt CM et al. Immunogenicity and efficacy of DNA vaccines encoding influenza A proteins in aged mice. Vaccine16(18), 1748–1755 (1998).
  • Donnelly JJ, Friedman A, Martinez D et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat. Med.1(6), 583–587 (1995).
  • Donnelly JJ, Friedman A, Ulmer JB, Liu MA. Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination. Vaccine15(8), 865–868 (1997).
  • Ennis FA, Rook AH, Qi YH et al. HLA restricted virus-specific cytotoxic T-lymphocyte responses to live and inactivated influenza vaccines. Lancet2(8252), 887–891 (1981).
  • Doherty PC, Turner SJ, Webby RG, Thomas PG. Influenza and the challenge for immunology. Nat. Immunol.7(5), 449–455 (2006).
  • Wise TG, Dolin R, Mazur MH, Ennis FA. Serologic responses after two sequential doses of influenza A/New Jersey/76 virus vaccine in normal young adults. J. Infect. Dis.136(Suppl.), S496–S499 (1977).
  • Gross PA. Reactogenicity and immunogenicity of bivalent influenza vaccine in one- and two-dose trials in children: a summary. J. Infect. Dis.136(Suppl.), S616–S625 (1977).
  • Johansson BE, Brett IC. Changing perspective on immunization against influenza. Vaccine25(16), 3062–3065 (2007).
  • Belshe RB. A review of attenuation of influenza viruses by genetic manipulation. Am. J. Respir. Crit. Care Med.152(4 Pt 2), S72–S75 (1995).
  • Kilbourne ED. An explanation of the interpandemic antigenic mutability of influenza viruses. J. Infect. Dis.128(5), 668–670 (1973).
  • Kilbourne ED. The molecular epidemiology of influenza. J. Infect. Dis.127(4), 478–487 (1973).
  • CDC. Prevention and control of influenza : recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.53(RR06), 1–40 (2004).
  • Besselaar TG, Blackburn NK, Schoub BD. The molecular characterization of influenza virus strains isolated in South Africa during 1993 and 1994. Res. Virol.147(4), 239–245 (1996).
  • Besselaar TG, Botha L, Mcanerney JM, Schoub BD. Antigenic and molecular analysis of influenza A (H3N2) virus strains isolated from a localised influenza outbreak in South Africa in 2003. J. Med. Virol.73(1), 71–78 (2004).
  • Wise TG, Dolin R, Mazur MH, Top FH Jr, Edelman R, Ennis FA. Serologic responses and systemic reactions in adults after vaccination with bivalent A/Victoria/75-A/New Jersey/76 and monovalent B/Hong Kong/72 influenza vaccines. J. Infect. Dis.136(Suppl.), S507–S517 (1977).
  • Ennis FA, Wise TG, Mclaren C, Verbonitz MW. Serological responses to whole and split A/New Jersey vaccines in humans and mice following priming infection with influenza A viruses. Dev. Biol. Stand.39, 261–266 (1977).
  • Mclaren C, Verbonitz MW, Daniel S, Grubbs GE, Ennis FA. Effect of priming infection on serologic response to whole and subunit influenza virus vaccines in animals. J. Infect. Dis.136(Suppl.), S706–S711 (1977).
  • Gross PA, Ennis FA. Influenza vaccine: split-product versus whole-virus types – how do they differ. N. Engl. J. Med.296(10), 567–568 (1977).
  • Gross PA, Ennis FA, Gaerlan PF, Denson LJ, Denning CR, Schiffman D. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. J. Infect. Dis.136(5), 623–632 (1977).
  • Hoskins TW, Davies JR, Smith AJ, Miller CL, Allchin A. Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ’s Hospital. Lancet1(8106), 33–35 (1979).
  • Gerentes L, Kessler N, Aymard M. Difficulties in standardizing the neuraminidase content of influenza vaccines. Dev. Biol. Stand.98, 189–196; discussion 197 (1999).
  • Tanimoto T, Nakatsu R, Fuke I et al. Estimation of the neuraminidase content of influenza viruses and split-product vaccines by immunochromatography. Vaccine23(37), 4598–4609 (2005).
  • Aymard M. Quantification of neuramidase (NA) protein content. Vaccine20(Suppl. 2), S59–S60 (2002).
  • Gravela C, Lib C, Wang J, Hashema A et al. Qualitative and quantitative analyses all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences. Vaccine28(36), 5774–5784 (2010).
  • Valette M, Aymard M. Quality control assessment of influenza and RSV testing in Europe: 2000–01 season. Euro. Surveill.7(11), 161–165 (2002).
  • Kilbourne ED, Couch RB, Kasel JA et al. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine13(18), 1799–1803 (1995).
  • Kilbourne ED, Cerini CP, Khan MW, Mitchell JW Jr, Ogra PL. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. J. Immunol.138(9), 3010–3013 (1987).
  • Kilbourne ED. Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans. J. Infect. Dis.134(4), 384–394 (1976).
  • Kendal AP, Noble GR, Dowdle WR. Neuraminidase content of influenza vaccines and neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations. J. Infect. Dis.136(Suppl.), S415–S424 (1977).
  • Johansson BE, Brett IC. Recombinant influenza B virus HA and NA antigens administered in equivalent amounts are immunogenically equivalent and induce equivalent homotypic and broader heterovariant protection in mice than conventional and live influenza vaccines. Hum. Vaccin.4(6), 420–424 (2008).
  • Johansson BE, Bucher DJ, Kilbourne ED. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J. Virol.63(3), 1239–1246 (1989).
  • Kilbourne ED, Christenson WN, Sande M. Antibody response in man to influenza virus neuraminidase following influenza. J. Virol.2(7), 761–762 (1968).
  • Kilbourne ED, Laver WG, Schulman JL, Webster RG. Antiviral activity of antiserum specific for an influenza virus neuraminidase. J. Virol.2(4), 281–288 (1968).
  • Bucher D, Palese P. The biologically active proteins of influenza virus: neuraminidase. In: The Influenza Viruses and Influenza. Kilbourne ED (Ed.). Academic Press, NY, USA, 83–123 (1975).
  • Air GM, Laver WG. The neuraminidase of influenza virus. Proteins6, 341–356 (1989).
  • Huang RT, Rott R, Wahn K, Klenk HD, Kohama T. The function of the neuraminidase in membrane fusion induced by myxoviruses. Virology107(2), 313–319 (1980).
  • Huang RT, Wahn K, Klenk HD, Rott R. Fusion between cell membrane and liposomes containing the glycoproteins of influenza virus. Virology104(2), 294–302 (1980).
  • Brett IC, Johansson BE. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology339(2), 273–280 (2005).
  • Couch RB, Kasel JA, Gerin JL, Schulman JL, Kilbourne ED. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J. Infect. Dis.129(4), 411–420 (1974).
  • Johansson BE, Grajower B, Kilbourne ED. Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice. Vaccine11(10), 1037–1039 (1993).
  • Johansson BE, Kilbourne ED. Immunization with purified N1 and N2 influenza virus neuraminidases demonstrates cross-reactivity without antigenic competition. Proc. Natl Acad. Sci. USA91(6), 2358–2361 (1994).
  • Johansson BE, Kilbourne ED. Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition. J. Virol.67(10), 5721–5723 (1993).
  • Couch RB, Douglas RG Jr, Fedson DS, Kasel JA. Correlated studies of a recombinant influenza-virus vaccine. 3. Protection against experimental influenza in man. J. Infect. Dis.124(5), 473–480 (1971).
  • Hocart M, Grajower B, Donabedian A, Pokorny B, Whitaker C, Kilbourne ED. Preparation and characterization of a purified influenza virus neuraminidase vaccine. Vaccine13(18), 1793–1798 (1995).
  • Schiff GKE, Smith G, Hackett C, Manoff S, Matthews J, Johansson B. Phase 2 clinical evaluation of an influenza A virus recombinant N2 neuraminidase vaccine. Presented at: The First European Influenza Congress, Hersonessos. Crete, Greece, 23–28 September 2000.
  • Martinet W, Saelens X, Deroo T et al. Protection of mice against a lethal influenza challenge by immunization with yeast-derived recombinant influenza neuraminidase. Eur. J. Biochem.247(1), 332–338 (1997).
  • Bosch BJ, Bodewes R, De Vries RP et al. Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets. J. Virol.84(19), 10366–10374 (2010).
  • Chen Z, Matsuo K, Asanuma H et al. Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs. Vaccine17(7–8), 653–659 (1999).
  • Chen Z, Kadowaki S, Hagiwara Y et al. Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine18(28), 3214–3222 (2000).
  • Rott R, Becht H, Orlich M. The significance of influenza virus neuraminidase in immunity. J. Gen. Virol.22(1), 35–41 (1974).
  • Gallagher M, Bucher DJ, Dourmashkin R, Davis JF, Rosenn G, Kilbourne ED. Isolation of immunogenic neuraminidases of human influenza viruses by a combination of genetic and biochemical procedures. J. Clin. Microbiol.20(1), 89–93 (1984).
  • Johansson BE, Matthews JT, Kilbourne ED. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine16(9–10), 1009–1015 (1998).
  • Johansson BE, Pokorny BA, Tiso VA. Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition. Vaccine20(11–12), 1670–1674 (2002).
  • Chen J, Fang F, Li X, Chang H, Chen Z. Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation. Vaccine23(34), 4322–4328 (2005).
  • Eickhoff TC, Meiklejohn G. Protection against Hong Kong influneza by adjuvant vaccine containing A2-Ann Arbor-67. Bull. World Health Organ.41(3), 562–563 (1969).
  • Monto AS, Kendal AP. Effect of neuraminidase antibody on Hong Kong influenza. Lancet1(7804), 623–625 (1973).
  • Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med.4(2), e59 (2007).
  • Lee JT, Air GM. Interaction between a 1998 human influenza virus N2 neuraminidase and monoclonal antibody Mem5. Virology345(2), 424–433 (2006).
  • Lee YJ, Sung HW, Choi JG et al. Effects of homologous and heterologous neuraminidase vaccines in chickens against H5N1 highly pathogenic avian influenza. Avian. Dis.51(Suppl. 1), S476–S478 (2007).
  • Beutner KR, Chow T, Rubi E, Strussenberg J, Clement J, Ogra PL. Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection. J. Infect. Dis.140(6), 844–850 (1979).
  • Johansson BE, Moran TM, Bona CA, Kilbourne ED. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. III. Reduced generation of neuraminidase-specific helper T cells in hemagglutinin-primed mice. J. Immunol.139(6), 2015–2019 (1987).
  • Johansson BE. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Vaccine17(15–16), 2073–2080 (1999).
  • Kilbourne ED. Influenza: viral determinants of the pathogenicity and epidemicity of an invariant disease of variable occurrence. Philos. Trans. R. Soc. Lond. B. Biol. Sci.288(1029), 291–297 (1980).
  • Powers DC, Smith GE, Anderson EL et al. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J. Infect. Dis.171(6), 1595–1599 (1995).
  • Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med.354(13), 1343–1351 (2006).
  • Treanor JJ, Wilkinson BE, Masseoud F et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine19(13–14), 1732–1737 (2001).
  • Price GE, Soboleski MR, Lo CY et al. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine27(47), 6512–6521 (2009).
  • Kilbourne ED, Johansson BE, Grajower B. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc. Natl Acad. Sci. USA87(2), 786–790 (1990).
  • Johansson BE, Kilbourne ED. Comparative long-term effects in a mouse model system of influenza whole virus and purified neuraminidase vaccines followed by sequential infections. J. Infect. Dis.162(4), 800–809 (1990).
  • Nayak B, Kumar S, Dinapoli JM et al. Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity. J. Virol.84(5), 2408–2420 (2010).
  • Buonagurio DA, Nakada S, Parvin JD, Krystal M, Palese P, Fitch WM. Evolution of human influenza A viruses over 50 years: rapid, uniform rate of change in NS gene. Science232(4753), 980–982 (1986).
  • Parvin JD, Moscona A, Pan WT, Leider JM, Palese P. Measurement of the mutation rates of animal viruses: influenza A virus and poliovirus type 1. J. Virol.59(2), 377–383 (1986).
  • Air GM, Laver WG, Webster RG, Els MC, Luo M. Antibody recognition of the influenza virus neuraminidase. Cold Spring Harb. Symp. Quant. Biol.54(Pt 1), 247–255 (1989).
  • Cate TR, Rayford Y, Nino D et al. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine28(9), 2076–2079 (2010).
  • Govorkova EA, Fang HB, Tan M, Webster RG. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob. Agents Chemother.48(12), 4855–4863 (2004).
  • Govorkova EA, Ilyushina NA, Mcclaren JL, Naipospos TS, Douangngeun B, Webster RG. Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. Antimicrob. Agents Chemother.53(7), 3088–3096 (2009).
  • Gubareva LV, Bethell R, Hart GJ, Murti KG, Penn CR, Webster RG. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J. Virol.70(3), 1818–1827 (1996).
  • Duan S, Boltz DA, Seiler P et al. Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog.6(7), e1001022 (2010).
  • Yen HL, Herlocher LM, Hoffmann E et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother.49(10), 4075–4084 (2005).
  • Carr J, Ives J, Kelly L et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res.54(2), 79–88 (2002).
  • Colman PM, Laver WG, Varghese JN et al. Three-dimensional structure of a complex of antibody with influenza virus neuraminidase. Nature326(6111), 358–363 (1987).
  • Colman PM, Tulip WR, Varghese JN et al. Three-dimensional structures of influenza virus neuraminidase-antibody complexes. Philos. Trans. R. Soc. Lond. B. Biol. Sci.323(1217), 511–518 (1989).
  • Hensley SE, Das SR, Gibbs JS et al. Influenza A virus hemagglutinin antibody escape promotes neuraminidase antigenic variation and drug resistance. PLoS One6(2), e15190 (2011).
  • Price PM, Reichelderfer CF, Johansson BE, Kilbourne ED, Acs G. Complementation of recombinant baculoviruses by coinfection with wild-type virus facilitates production in insect larvae of antigenic proteins of hepatitis B virus and influenza virus. Proc. Natl Acad. Sci. USA86(5), 1453–1456 (1989).
  • Hervas-Stubbs S, Rueda P, Lopez L, Leclerc C. Insect baculoviruses strongly potentiate adaptive immune responses by inducing type 1 IFN. J. Immunol.178(4), 2361–2369 (2007).
  • Sultana I, Gao J, Markoff L, Eichelberger MC. Influenza neuraminidase-inhibiting antibodies are induced in the presence of zanamivir. Vaccine29(14), 2601–2606 (2011).
  • Varghese JN, Laver WG, Colman PM. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature303(5912), 35–40 (1983).
  • Varghese JN, Mckimm-Breschkin JL, Caldwell JB, Kortt AA, Colman PM. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins14(3), 327–332 (1992).
  • Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature303(5912), 41–44 (1983).
  • Colman PM, Ward CW. Structure and diversity of influenza virus neuraminidase. Curr. Top. Microbiol. Immunol.114, 177–255 (1985).
  • Colman PM. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci.3(10), 1687–1696 (1994).
  • Dimmock NJ. Dependence of the activity of an influenza virus neuraminidase upon Ca2+. J. Gen. Virol.13(3), 481–483 (1971).
  • Wilson VW Jr, Rafelson MR Jr. Studies on the neuraminidases of influenza virus. 3. Stimulation of activity by bivalent cations. Biochim. Biophys. Acta146(1), 160–166 (1967).
  • Rafelson ME Jr, Schneir M, Wilson VW Jr. Studies on the neuraminidase of influenza virus. II. Additional properties of the enzymes from the Asian and Pr 8 strains. Arch. Biochem. Biophys.103, 424–430 (1963).
  • Carroll SM, Paulson JC. Complete metal ion requirement of influenza virus N1 neuraminidases. Brief report. Arch. Virol.71(3), 273–277 (1982).
  • Johansson BE, Brett IC. Variation in the divalent cation requirements of influenza a virus N2 neuraminidases. J. Biochem.134(3), 345–352 (2003).
  • Brett IC, Johansson BE. Variation in the divalent cation requirements of influenza A virus N1 neuraminidases. J. Biochem.139(3), 439–447 (2006).
  • Sylte MJ, Suarez DL. Influenza neuraminidase as a vaccine antigen. Curr. Top. Microbiol. Immunol.333, 227–241 (2009).
  • Colman PM. Structural basis of antigenic variation: studies of influenza virus neuraminidase. Immunol. Cell Biol.70(Pt 3), 209–214 (1992).
  • Colman PM. Structure of antibody-antigen complexes: implications for immune recognition. Adv. Immunol.43, 99–132 (1988).
  • Sylte MJ, Hubby B, Suarez DL. Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection. Vaccine25(19), 3763–3772 (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.